Drugs / NYVAC-B
NYVAC-B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00961883 | Aug 2009 → Jan 2013 | HIV infectious disease | HIV Vaccine Trials Network | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NYVAC-B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00961883 ↗ |
| Known as | New York Vaccinia | “New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU” NCT00961883 ↗ |
| Known as | NYVAC | “New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU” NCT00961883 ↗ |
| Modality | Vaccine | “two vaccines expressing synthetic HIV proteins: NYVAC-B (a poxvirus), and rAd5 (an adenovirus).” NCT00961883 ↗ |
| Route | Intramuscular | “New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 \^7 PFU” NCT00961883 ↗ |